Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)

Abstract

6119 Background: IM (Glivec, Gleevec) is an oral targeted therapy with unprecedented efficacy in CML and GIST. Prescription compliance and persistency of pts receiving IM were measured by analysis of pt-level pharmacy claims data. Methods: Compliance and persistency were determined by analyzing the prescription-filling activity of pts (N=4043) compared with the prescribing activity of their physicians (N=3316) using pt pharmacy records accrued over 24 months (1/03–12/04). Observed average daily consumption (DACON) and average prescribed days of therapy were calculated and compared. Also, compliance and persistency were examined by pt demographics and initial IM dose prescribed. Results: Overall compliance (defined as medication possession ratio = apparent mg taken/mg prescribed) was 75%, with CML pts showing slightly greater compliance (78%) than GIST pts (73%). Fifty percent of pts were 100% compliant, the greatest compliance being found in pts initially treated with IM 300 or 400 mg/day (77%). Persistency (time on therapy without significant gaps in refills) averaged 255 days over 24 months. The most persistent pts were those initially given 300 or 400 mg/day (13.0 and 12.9 months, respectively). DACON was 400 mg/day for 65% of patients, but fluctuated above and below 400 mg/day in 18% and 17% of pts, respectively. Conclusions: This is the first assessment of pt compliance and persistency with prescribed IM therapy. Although less pronounced than with most other non-oncology products, suboptimal compliance and persistency with IM are a concern as doses <300–400 mg may result in plasma levels lower than needed to eliminate cancer cells. Patient support programs and improved communication on the importance of adhering to recommended dosing could potentially optimize outcome and further reduce risk of relapse and progression. [Table: see text]

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

“…86,87 With imatinib treatment, an analysis of patient-level pharmacy claims data in 4043 imatinib-treated patients (CML or GI stromal tumors) found that patients with CML took an average of 78% of their prescribed imatinib therapy during the 24-month study period. 88 In a separate analysis of pharmacy claims, the adherence rate to imatinib at doses of 400 to less than 600 mg per day was 66%, which decreased to 52% for patients prescribed 600 to less than 800 mg per day (Po0.0001). 89 A retrospective analysis of electronic healthcare claims data from a US-managed care provider found that 31% of 267 adult patients with CML interrupted their treatment, that is, failed to refill imatinib within 30 days from the run-out date of the prior prescription.…”

Improving Adherence to Oral Cancer Therapy in Clinical Practice

“…37 Adherence to imatinib, based on MPR or pill-count data, ranges from 74-93%. 39,40,42,43,50 A recent study used MPR data to provide initial validation of a 10question patient-administered questionnaire, which was able to reliably identify patients with an MPR less than 90%. 50 Such questionnaires, validated by more objective measures, may be useful in identifying patients who may benefit from intervention.…”

Treating Chronic Myeloid Leukemia

“…When choosing among BCR-ABL inhibitors, differences in treatment-related factors such as dosing regimen, side effects, evidence and immediacy of benefit, cost of treatment, and complexity of treatment regimen should be considered (Boonen et al, 2008;Darkow et al, 2007;Osterberg & Blaschke, 2005;Partridge, Avorn, Wang, & Winer, 2002;Ruddy, Mayer, & Partridge, 2009;St. Charles et al, 2009;Tsang, Rudychev, & Pescatore, 2006;Yood et al, 2012).…”